Literature DB >> 32976876

Can radiation-recall predict long lasting response to immune checkpoint inhibitors?

Eric Deutsch1, Benjamin Besse2, Jérôme Le Pavec3, Cécile Le Péchoux4, Angela Botticella4, Samy Ammari5, Caroline Even6, Caroline Robert2, Antonin Levy7.   

Abstract

RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti CTLA4; Anti PD-L1; Anti-PD1; Radioimmunotherapy

Year:  2020        PMID： 32976876     DOI： 10.1016/j.radonc.2020.09.037

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  3 in total

1.  The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.

Authors:  Shwetha H Manjunath; Adam D Cohen; Simon F Lacey; Megan M Davis; Alfred L Garfall; J Joseph Melenhorst; Russell Maxwell; W Tristram Arscott; Amit Maity; Joshua A Jones; John P Plastaras; Edward A Stadtmauer; Bruce L Levine; Carl H June; Michael C Milone; Ima Paydar
Journal:  Clin Cancer Res       Date:  2021-09-15       Impact factor: 13.801

2.  Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.

Authors:  Xianghua Ye; Jinsong Yang; Justin Stebbing; Ling Peng
Journal:  BMC Pulm Med       Date:  2022-02-05       Impact factor: 3.317

3.  Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review.

Authors:  Ecem Yigit; Deniz Can Guven; Sercan Aksoy; Gozde Yazici
Journal:  Cureus       Date:  2021-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.